Langenbeck's archives of surgery · 2011
Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Königsrainer Ingmar, Beckert Stefan, Becker Sven, Zieker Derek, Fehm Tanja, Grischke Eva-Maria, Lauk Olivia, Glatzle Jörg, Brücher Björn, Wallwiener Diethelm, Königsrainer Alfred
Аннотация
PURPOSE: Peritoneal recurrence of ovarian cancer is frequent after primary surgery and chemotherapy and has poor long-term survival. De novo cytoreductive surgery is crucial with the potential to improve prognosis, especially when combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
METHODS: The sampled data of 40 consecutive patients were retrospectively analyzed. Thirty-one patients were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.
RESULTS: No patient was lost in the perioperative period, and the combined procedure was performed with acceptable morbidity. Colon-preserving cytoreductive surgery was associated with reduced morbidity.
CONCLUSIONS: Patients suffering from peritoneal recurrence of ovarian cancer should be considered for radical reoperation with HIPEC in a center with expertise in multimodal therapeutic options. Organ-preserving cytoreductive surgery allows complete cytoreduction with the goal of decreasing morbidity.
METHODS: The sampled data of 40 consecutive patients were retrospectively analyzed. Thirty-one patients were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.
RESULTS: No patient was lost in the perioperative period, and the combined procedure was performed with acceptable morbidity. Colon-preserving cytoreductive surgery was associated with reduced morbidity.
CONCLUSIONS: Patients suffering from peritoneal recurrence of ovarian cancer should be considered for radical reoperation with HIPEC in a center with expertise in multimodal therapeutic options. Organ-preserving cytoreductive surgery allows complete cytoreduction with the goal of decreasing morbidity.
Предметные рубрики MeSH
AdultAgedAntineoplastic AgentsCohort StudiesCombined Modality TherapyFemaleHumansHyperthermia, InducedInfusions, ParenteralKaplan-Meier EstimateMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingOvarian NeoplasmsOvariectomyPeritoneal NeoplasmsPrognosisRetrospective StudiesRisk AssessmentStatistics, NonparametricSurvival AnalysisTreatment Outcome